ARUP Laboratories Offers Antiretroviral Drug Resistance Testing for HIV-1

Apr 10, 2001, 01:00 ET from ARUP Laboratories, Inc.

    SALT LAKE CITY, April 10 /PRNewswire/ -- ARUP Laboratories, Inc.
 (www.aruplab.com), a national, specialty diagnostic reference laboratory,
 announced that it is now offering antiretroviral drug resistance testing for
 HIV-1 in partnership with Tibotec-Virco, an international biotechnology
 company specializing in drug discovery, molecular diagnostics, and
 pharmacogenomics.  Under the agreement, ARUP will offer Tibotec-Virco's
 VirtualPhenotype(TM) assay, which combines genotypic information with a
 quantitative prediction of phenotypic resistance.
     Current treatment for HIV-1 infected individuals includes the use of
 combination antiretroviral drug therapy to suppress HIV-1 replication and
 decrease disease progression, thereby improving clinical status.  Despite
 advancements in HIV-1 drug therapy, treatment failures are commonly seen
 because of preexisting or selected drug-resistant viral strains.  The
 genotypic and phenotypic assays now offered by ARUP, including the
 VirtualPhenotype(TM) assay, allow clinicians to predict HIV drug resistance.
 Specifically, the VirtualPhenotype(TM) system compares a patient's viral
 sequence to more than 17,000 samples with matched phenotypic and genotypic
 information to determine which drugs can actively fight that particular viral
 strain.  The VirtualPhenotype(TM) test is the only quantitative approach
 available for predicting HIV resistance from genotypic information.
     "We are very pleased to enhance our test portfolio with Tibotec-Virco's
 HIV drug resistance testing services, which we believe are among the most
 advanced and comprehensive available," said David Hillyard, M.D., Medical
 Director of Molecular Infectious Diseases for ARUP Laboratories.
     Resistance testing can be used as a guide for treating patients who are
 failing therapy and in HIV-infected pregnant women.  It should be considered
 for treating patients with established and primary infection.  The
 determination of resistance mutations before beginning therapy may also be
 helpful in designing more effective treatment regimens for patients.
     "We hope that this partnership with ARUP will have a positive impact on
 the treatment outcome for people living with HIV and AIDS," commented Wim
 Swyzen, M.D., Regional Managing Director for Virco USA & Canada.  "We are
 delighted that ARUP will help us expand the distribution of these important
 services in the United States."
 
     Background Information
     ARUP Laboratories was formed in 1984 as a full-service reference
 laboratory in the United States and is owned by the Department of Pathology at
 the University of Utah Health Sciences Center.  ARUP performs specialty,
 esoteric testing that supplements the diagnostic testing available in local
 communities.  ARUP, with revenue of greater than $100 million, provides
 diagnostic testing services for clients and hospitals throughout the United
 States, including university teaching hospitals, multihospital groups, major
 commercial laboratories, group purchasing organizations, military and
 government facilities, major clinics, and major pharmaceutical firms.  ARUP
 remains at the forefront of innovative research and development in clinical
 and experimental laboratory medicine, led by the efforts of the ARUP Institute
 for Clinical and Experimental Pathology.
 
     Tibotec-Virco was formed from the merger of Virco Group NV and Tibotec
 Group NV on March 14, 2001.  The combined group brings together the
 complementary expertise of Tibotec in drug discovery and development and of
 Virco in pharmacogenomics and molecular diagnostics.  Tibotec-Virco is a
 multinational biotechnology company with operating subsidiaries in the United
 States, Belgium, the United Kingdom, and Ireland.
 
 

SOURCE ARUP Laboratories, Inc.
    SALT LAKE CITY, April 10 /PRNewswire/ -- ARUP Laboratories, Inc.
 (www.aruplab.com), a national, specialty diagnostic reference laboratory,
 announced that it is now offering antiretroviral drug resistance testing for
 HIV-1 in partnership with Tibotec-Virco, an international biotechnology
 company specializing in drug discovery, molecular diagnostics, and
 pharmacogenomics.  Under the agreement, ARUP will offer Tibotec-Virco's
 VirtualPhenotype(TM) assay, which combines genotypic information with a
 quantitative prediction of phenotypic resistance.
     Current treatment for HIV-1 infected individuals includes the use of
 combination antiretroviral drug therapy to suppress HIV-1 replication and
 decrease disease progression, thereby improving clinical status.  Despite
 advancements in HIV-1 drug therapy, treatment failures are commonly seen
 because of preexisting or selected drug-resistant viral strains.  The
 genotypic and phenotypic assays now offered by ARUP, including the
 VirtualPhenotype(TM) assay, allow clinicians to predict HIV drug resistance.
 Specifically, the VirtualPhenotype(TM) system compares a patient's viral
 sequence to more than 17,000 samples with matched phenotypic and genotypic
 information to determine which drugs can actively fight that particular viral
 strain.  The VirtualPhenotype(TM) test is the only quantitative approach
 available for predicting HIV resistance from genotypic information.
     "We are very pleased to enhance our test portfolio with Tibotec-Virco's
 HIV drug resistance testing services, which we believe are among the most
 advanced and comprehensive available," said David Hillyard, M.D., Medical
 Director of Molecular Infectious Diseases for ARUP Laboratories.
     Resistance testing can be used as a guide for treating patients who are
 failing therapy and in HIV-infected pregnant women.  It should be considered
 for treating patients with established and primary infection.  The
 determination of resistance mutations before beginning therapy may also be
 helpful in designing more effective treatment regimens for patients.
     "We hope that this partnership with ARUP will have a positive impact on
 the treatment outcome for people living with HIV and AIDS," commented Wim
 Swyzen, M.D., Regional Managing Director for Virco USA & Canada.  "We are
 delighted that ARUP will help us expand the distribution of these important
 services in the United States."
 
     Background Information
     ARUP Laboratories was formed in 1984 as a full-service reference
 laboratory in the United States and is owned by the Department of Pathology at
 the University of Utah Health Sciences Center.  ARUP performs specialty,
 esoteric testing that supplements the diagnostic testing available in local
 communities.  ARUP, with revenue of greater than $100 million, provides
 diagnostic testing services for clients and hospitals throughout the United
 States, including university teaching hospitals, multihospital groups, major
 commercial laboratories, group purchasing organizations, military and
 government facilities, major clinics, and major pharmaceutical firms.  ARUP
 remains at the forefront of innovative research and development in clinical
 and experimental laboratory medicine, led by the efforts of the ARUP Institute
 for Clinical and Experimental Pathology.
 
     Tibotec-Virco was formed from the merger of Virco Group NV and Tibotec
 Group NV on March 14, 2001.  The combined group brings together the
 complementary expertise of Tibotec in drug discovery and development and of
 Virco in pharmacogenomics and molecular diagnostics.  Tibotec-Virco is a
 multinational biotechnology company with operating subsidiaries in the United
 States, Belgium, the United Kingdom, and Ireland.
 
 SOURCE  ARUP Laboratories, Inc.